NCT06099184CompletedPhase 2
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)
Source: ClinicalTrials.gov · Last updated 4 Mar 2025
Brief summary (registry, in English)
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 19 Oct 2023
- Start date
- 15 Jan 2024
- Primary completion date
- 24 Oct 2024
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Diseases
- Diabetic eye disease
- NCT number
- NCT06099184
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 27
- From 15 Jan 2024 to the primary completion date, 24 Oct 2024
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any current or history of ocular disease other than DME
- Active ocular inflammation or active infection in either eye at Baseline (Day 1).
Other
- BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.
Who the study is looking for
- Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit
- Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit.
- BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Erie | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Hagerstown | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Lemont | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Lynchburg | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Phoenix | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Reno | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.